Canadian biopharmaceutical company Avicanna, which focuses on the development, manufacturing, and commercialisation of plant-derived cannabinoid-based products, has appointed Ozgur Kilic to its board of directors, effective 1 April 2026, following the resignation of John McVicar, according to The Manila Times.

Kilic brings more than 20 years of experience at global public companies and private equity-backed pharmaceutical firms across the US, UK, Italy, and Switzerland, having held senior roles as chief executive, chief financial officer, and chief operating officer.

Ozgur Kilic said: "I am honored and excited to join the Board of Directors at Avicanna at such a pivotal time in the company's evolution. The company is reaching a meaningful value inflection point, driven by a differentiated portfolio of existing products and a promising pharmaceutical pipeline focused on addressing significant unmet medical needs."

Kilic holds a BA in Business Administration and History from Koc University and an MBA in Finance and Investment from Stuttgart Institute of Management and Technology. He is also qualified as an Associate Chartered Management Accountant and Chartered Global Management Accountant.

The appointment comes as Toronto Stock Exchange-listed Avicanna advances plans to expand its presence in the United States and strengthen its international commercial footprint.

Avicanna's pipeline is focused on addressing unmet medical needs through cannabinoid-based therapeutics, a segment attracting increasing attention from pharmaceutical developers as regulatory frameworks evolve across key global markets.

View the complete report for further details on Avicanna's board changes and strategic direction.